Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 60 Sep 16 – Oct 15, 2026
- Disclosed funding
- $2.1B 44 disclosed amounts
- Median round
- $16.3M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| OT OMass TherapeuticsCompany profile OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings. OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings. | $310M | Series CSeries C+ | Biotech | United Kingdom | Investors | |
| AP Acta PharmaceuticalsCompany profile Develops investigational medicines for early intervention in Alzheimer’s disease. Develops investigational medicines for early intervention in Alzheimer’s disease. | $24M | Total seed financingSeed | Biotech | United States | Investors Undisclosed | |
| SB Silvia BioCompany profile Cell profiling and media additives for more predictable biopharmaceutical manufacturing. Cell profiling and media additives for more predictable biopharmaceutical manufacturing. | £3M | Seed | Biotech | United Kingdom | Investors | |
| H Enzyme-based catalysts for industrial chemical manufacturing. | $8M | Series A first closeSeries A | Biotech | United Kingdom | Investors | |
| s Quantitative biomarkers for diseases driven by protein aggregation. | €12M | Mixed financingUndisclosed | Biotech | Germany | Investors | |
| M MolagriCompany profile Molagri develops targeted crop-protection products for growers facing pesticide resistance. Molagri develops targeted crop-protection products for growers facing pesticide resistance. | Undisclosed | Seed | Biotech, Agritech | Canada | Investors | |
| O Climate-resilient cereal genetics for commercial seed programs. | €5M | Seed | Biotech, Agritech | Sweden | Investors | |
| B BoltzCompany profile Boltz builds biomolecular AI models and software for molecular design and drug-discovery research. Boltz builds biomolecular AI models and software for molecular design and drug-discovery research. | Undisclosed | Planned strategic investmentUndisclosed | Biotech | United States | Investors | |
| UB Undecimal BioCompany profile Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease. Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease. | $18M | Seed | Biotech | United Kingdom | Investors | |
| GB Giraffe Bio develops biochemical reagents for mineral recovery. | $6.4M | Seed | Biotech | Argentina | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Sep 16, 2026
- 1Novo Holdings
OMass Therapeutics, AnaCardio, Breye Therapeutics
3rounds3led - 2Industrifonden
OlsAro, AnaCardio, EnginZyme
3rounds1led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
3rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
3rounds1led - 5Forbion
OMass Therapeutics, Sling Therapeutics, Inc.
2rounds2led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.